Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Junshi Biosciences Doses First Patient in Phase 3 Trial of JS207-JS007 for Advanced Liver Cancer

By Public Technologies
  • Junshi Biosciences completed first-patient dosing in a Phase 3 trial of JS207 with JS007 on Oct. 29, 2026.
  • The trial compares the combination with toripalimab plus bevacizumab as a first-line treatment for advanced hepatocellular carcinoma.
  • Planned enrollment is 560 patients, with overall survival and progression-free survival as primary endpoints.
  • Phase 2 results were presented at the European Society for Medical Oncology Congress in October 2026.
  • Those results showed strong anti-tumor activity; the combination was well tolerated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290704PRIMZONEFULLFEED9856020) on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.